On August 8, 2024, Douglas Treff, Director at Crocs Inc (NASDAQ:CROX), completed a sale of 10,594 shares of the company’s stock. The transaction was reported through an SEC filing on the same day. Following this transaction, the insider now owns 81,254 shares of Crocs Inc.

Crocs Inc., known for its innovative casual shoes for men, women and children, uses the company’s proprietary closed-cell resin Croslite to create lightweight, non-marking and odor-resistant shoes. This unique offering has helped Crocs carve out a niche in the footwear industry.

Over the past year, the insider has sold a total of 19,591 shares and purchased 2,114 shares. The recent sale is part of a broader trend seen at Crocs Inc., which has seen 16 insider sales and 4 insider purchases over the past year.

Crocs Inc. shares were trading at $132.38 on the day of the transaction. The company has a market capitalization of approximately $7.85 billion. The price-to-earnings ratio is 9.95, which is below the industry median of 19.78 and the company’s historical median.

The stock is valued at $130.81 according to GF Value, which results in a price to GF Value ratio of 1.01, indicating that the stock is fairly valued. GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business development estimates from analysts.

This insider sale may be of interest to investors who track ownership changes and evaluate the company’s current stock valuation relative to its historical performance and industry standards.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.